Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomised, double-blind, phase III transition study

Annals of the Rheumatic Diseases

Volumn 77, Issue 2, 2018, Pages 234-240

  Smolen, Josef S ^a   Choe, Jung Yoon ^b   Prodanovic, Nenad ^c   Niebrzydowski, Jaroslaw ^d   Staykov, Ivan ^e   Dokoupilova, Eva ^f,g   Baranauskaite, Asta ^h   Yatsyshyn, Roman ⁱ   Mekic, Mevludin ^j   Porawska, Wieslawa ^k   Ciferska, Hana ^l   Jedrychowicz Rosiak, Krystyna ^m   Zielinska, Agnieszka ⁿ   Lee, Younju ^o   Rho, Young Hee ^o  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Catholic University of Daegu   (South Korea)

^c Clinical Center of Banja Luka   (Bosnia and Herzegovina)

^d Medica Pro Familia   (Poland)

^e MHAT   (Bulgaria)

^f Medical Plus Sro   (Czech Republic)

^g UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^h LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

ⁱ Internal Medicine 1 Department   (Ukraine)

^j University Clinical Centre of Sarajevo   (Bosnia and Herzegovina)

^k Poznanski Osrodek Medyczny Novamed   (Poland)

^l CHARLES UNIVERSITY   (Czech Republic)

^m MCBK SC   (Poland)

ⁿ Medica Pro Familia Sp z oo Spolka Komandytowo Akcyjna   (Poland)

^o Samsung Bioepis Co Ltd   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; CORTICOSTEROID; DRUG ANTIBODY; FOLIC ACID; INFLIXIMAB; METHOTREXATE; PARACETAMOL; SB 2; UNCLASSIFIED DRUG; ANTIBODY;

ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; BASAL CELL CARCINOMA; BRONCHITIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMATOMA; HUMAN; IMMUNOGENICITY; INFECTION; LATENT TUBERCULOSIS; LIP CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; THYROID CANCER; TONSILLITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UROSEPSIS; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLIXIMAB; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85041510862     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211741     Document Type: Article

References (24)

1. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82.
2. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.
3. Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann Rheum Dis 2014;73:2010-21.
4. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206.
5. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care 2015.
6. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. http://www. ema. europa. eu/ docs/ en-GB/ document-library/Scientific-guideline/ 2012/ 06/ WC500128686. pdf (accessed 12 Apr 2017).
7. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. http ://w ww.f da.g ov/d ownl oads /Drugs/ GuidanceComplianceRegulato ryIn form ation/ Gui dances / UCM291128. pdf (accessed 12 Apr 2017).
8. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:58-64.
9. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:51-7.
10. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
11. Kay J. Editorial: biosimilars: new or deja vu? Arthritis Rheumatol 2016;68:1049-52.
12. Janssen Biologics B.V. Summary of product characteristics: Remicade. http://www. ema. europa. eu/ docs/ en-GB/ document-library/ EPAR-Product-Information/ human/ 000240/ WC500050888. pdf (accessed 28 Feb 2017).
13. Shin D, Kim Y, Kim YS, et al. A randomized, phase I pharmacokinetic study comparing SB2 and Infliximab reference product (Remicade(®)) in healthy subjects. BioDrugs 2015;29:381-8.
14. Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). MAbs 2017;9:365-83.
15. European Medicines Agency. Summary of opinion (initial authorisation). Flixabi. Infliximab. http://www. ema. europa. eu/ docs/ en-GB/ document-library/ Summary-of-opinion-Initial-authorisation/ human/ 004020/ WC500203991. pdf (accessed 12 Apr 2017).
16. Samsung Bioepis. Samsung Bioepis' Biologics License Application for SB2 infliximabb: Newsroom. http://www. samsungbioepis. com/ en/ newsroom/ detail/ Samsung-Bioepis-Biologics-License-Application-for-SB2-Infliximab-Biosimilar-Accepted-by-FDA. html (accessed 12 Apr 2017).
17. Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology 2017;56:1771-1779.
18. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: american college of rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7.
19. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304-16.
20. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017;76:1426-31.
21. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355-63.
22. Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis 2017;76:1986-91.
23. Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol 2017;176:928-38.
24. Weissenfeld J, Stock S, Lüngen M, et al. The nocebo effect: a reason for patients' nonadherence to generic substitution? Pharmazie 2010;65:451-6.